Literature DB >> 30515715

Fungal Neurotoxins and Sporadic Amyotrophic Lateral Sclerosis.

Peter W French1, Russell Ludowyke2, Gilles J Guillemin3.   

Abstract

We review several lines of evidence that point to a potential fungal origin of sporadic amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neuron disease (MND) in adults. It is a progressive and fatal disease. Approximately 90% cases of ALS are sporadic, and 5-10% are due to genetic mutations (familial). About 25 genes implicated in familial ALS have been identified so far, including SOD1 and TARDBP, the gene encoding 43 kDa transactive response (TAR) DNA-binding protein (TDP-43). Despite intensive research over many decades, the aetiology of sporadic ALS is still unknown. An environmental cause, including grass or soil-associated fungal infections, is suggested from a range of widely diverse lines of evidence. Clusters of ALS have been reported in soccer players, natives of Guam and farmers. Grass-associated fungi are known to produce a range of neurotoxins and, in symbiotic associations, high levels of fungal SOD1. Exposure of neurons to fungal neurotoxins elicits a significant increase in glutamate production. High levels of glutamate stimulate TDP-43 translocation and modification, providing a link between fungal infection and one of the molecular and histologic hallmarks of sporadic ALS. A recent study provided evidence of a variety of fungi in the cerebrospinal fluid and brain tissue of ALS patients. This review provides a rational explanation for this observation. If a fungal infection could be confirmed as a potential cause of ALS, this could provide a straightforward treatment strategy for this fatal and incurable disease.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Fungi; Motor neuron disease; Mycotoxin; Sporadic ALS

Mesh:

Substances:

Year:  2018        PMID: 30515715     DOI: 10.1007/s12640-018-9980-5

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  90 in total

1.  Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death.

Authors:  C E Sabel; P J Boyle; M Löytönen; A C Gatrell; M Jokelainen; R Flowerdew; P Maasilta
Journal:  Am J Epidemiol       Date:  2003-05-15       Impact factor: 4.897

Review 2.  Management of motor neurone disease.

Authors:  R S Howard; R W Orrell
Journal:  Postgrad Med J       Date:  2002-12       Impact factor: 2.401

3.  Excess incidence of ALS in young Gulf War veterans.

Authors:  Robert W Haley
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

4.  Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players.

Authors:  Adriano Chiò; Gianmartino Benzi; Maurizia Dossena; Roberto Mutani; Gabriele Mora
Journal:  Brain       Date:  2005-01-05       Impact factor: 13.501

Review 5.  Disease clustering: the example of ALS, PD, dementia and hereditary ataxias in Italy.

Authors:  Andrea Malaspina; Dario Alimonti; Tino Emanuele Poloni; Mauro Ceroni
Journal:  Funct Neurol       Date:  2002 Oct-Dec

Review 6.  Return of the cycad hypothesis - does the amyotrophic lateral sclerosis/parkinsonism dementia complex (ALS/PDC) of Guam have new implications for global health?

Authors:  P G Ince; G A Codd
Journal:  Neuropathol Appl Neurobiol       Date:  2005-08       Impact factor: 8.090

Review 7.  Pathology of common pulmonary fungal infections.

Authors:  A K Haque
Journal:  J Thorac Imaging       Date:  1992-09       Impact factor: 3.000

8.  Superoxide dismutase influences the virulence of Cryptococcus neoformans by affecting growth within macrophages.

Authors:  Gary M Cox; Thomas S Harrison; Henry C McDade; Carlos P Taborda; Garrett Heinrich; Arturo Casadevall; John R Perfect
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Mechanisms for activating Cu- and Zn-containing superoxide dismutase in the absence of the CCS Cu chaperone.

Authors:  Mark C Carroll; Jody B Girouard; Janella L Ulloa; Jamuna R Subramaniam; Phillip C Wong; Joan Selverstone Valentine; Valeria Cizewski Culotta
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

10.  Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.

Authors:  Paul Alan Cox; Sandra Anne Banack; Susan J Murch
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-11       Impact factor: 11.205

View more
  6 in total

Review 1.  Brain diseases in changing climate.

Authors:  Joanna A Ruszkiewicz; Alexey A Tinkov; Anatoly V Skalny; Vasileios Siokas; Efthimios Dardiotis; Aristidis Tsatsakis; Aaron B Bowman; João B T da Rocha; Michael Aschner
Journal:  Environ Res       Date:  2019-08-08       Impact factor: 6.498

Review 2.  Approaches to Gene Modulation Therapy for ALS.

Authors:  Katharina E Meijboom; Robert H Brown
Journal:  Neurotherapeutics       Date:  2022-09-06       Impact factor: 6.088

Review 3.  Microbial Infections Are a Risk Factor for Neurodegenerative Diseases.

Authors:  Sarah K Lotz; Britanie M Blackhurst; Katie L Reagin; Kristen E Funk
Journal:  Front Cell Neurosci       Date:  2021-07-07       Impact factor: 5.505

Review 4.  Mold, Mycotoxins and a Dysregulated Immune System: A Combination of Concern?

Authors:  Stephanie Kraft; Lisa Buchenauer; Tobias Polte
Journal:  Int J Mol Sci       Date:  2021-11-12       Impact factor: 5.923

Review 5.  Neuroimmune Crosstalk Between the Peripheral and the Central Immune System in Amyotrophic Lateral Sclerosis.

Authors:  Weiyi Yu; Ji He; Xiying Cai; Zhou Yu; Zhangyu Zou; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2022-05-03       Impact factor: 5.750

Review 6.  Neuroinflammation: An Integrating Overview of Reactive-Neuroimmune Cell Interactions in Health and Disease.

Authors:  Rodolfo Kölliker-Frers; Lucas Udovin; Matilde Otero-Losada; Tamara Kobiec; María Inés Herrera; Jorge Palacios; Gabriela Razzitte; Francisco Capani
Journal:  Mediators Inflamm       Date:  2021-05-31       Impact factor: 4.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.